Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$2.39 USD
+0.06 (2.58%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.38 -0.01 (-0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Lexicon Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -177.12 | -101.94 | -87.76 | -58.57 | 130.13 |
Depreciation/Amortization & Depletion | 2.33 | 1.17 | 0.35 | 3.95 | 33.76 |
Net Change from Assets/Liabilities | 2.66 | 0.40 | -10.23 | 31.08 | -58.29 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 10.24 | 11.52 | 10.63 | -119.42 | 8.20 |
Net Cash From Operating Activities | -161.90 | -88.85 | -87.02 | -142.97 | 113.81 |
Property & Equipment | -0.47 | -1.33 | -1.22 | 10.93 | -0.07 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -49.47 | -69.75 | 3.33 | 369.83 | -155.79 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -49.94 | -71.08 | 2.11 | 380.76 | -155.86 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 138.00 | 93.34 | 34.41 | 68.94 | -0.94 |
Issuance (Repayment) of Debt | 49.96 | 48.87 | -11.70 | -216.58 | -1.29 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 187.96 | 142.21 | 22.71 | -147.64 | -2.23 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -23.88 | -17.72 | -62.20 | 90.15 | -44.27 |
Cash at Beginning of Period | 46.35 | 64.07 | 126.26 | 36.11 | 80.39 |
Cash at End of Period | 22.47 | 46.35 | 64.07 | 126.26 | 36.11 |
Diluted Net EPS | -0.80 | -0.62 | -0.60 | -0.53 | 1.16 |
Fiscal Year End for Lexicon Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -48.40 | -177.12 | -127.36 | -76.84 |
Depreciation/Amortization & Depletion | NA | 0.66 | 2.33 | 1.56 | 0.79 |
Net Change from Assets/Liabilities | NA | -11.47 | 2.66 | 6.94 | -0.92 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 4.08 | 10.24 | 7.52 | 7.23 |
Net Cash From Operating Activities | NA | -55.13 | -161.90 | -111.35 | -69.73 |
Property & Equipment | NA | 0.00 | -0.47 | -0.47 | -0.39 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -110.22 | -49.47 | -101.37 | -62.13 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -110.22 | -49.94 | -101.84 | -62.52 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 239.78 | 138.00 | 138.00 | 138.21 |
Issuance (Repayment) of Debt | NA | 0.00 | 49.96 | 49.96 | 49.96 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.40 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 239.38 | 187.96 | 187.96 | 188.17 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 74.03 | -23.88 | -25.23 | 55.93 |
Cash at Beginning of Period | NA | 22.47 | 46.35 | 46.35 | 46.35 |
Cash at End of Period | NA | 96.49 | 22.47 | 21.12 | 102.27 |
Diluted Net EPS | NA | -0.20 | -0.20 | -0.21 | -0.22 |